EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Conditional Mutant MAPT Overexpression in Neural Organoids Elicits Robust Tau Accumulation and Pathological Transcriptomic Responses

Andrew Kjar, Hyosung Kim, Madeline R. Spetz, Zev Jarrett, Melanie Fernandez, Jaime Wang, Maria L. Russotti, Caroline Bodnya, Daniel Chavarria, Timothy J. Hohman, Vivian Gama, Brad Grueter, Jonathan M. Brunger, Ethan S. Lippmann

ACS Chemical Neuroscience · 2026-11-04 · 17 (21) · 3501-3516

DOI: 10.1021/acschemneuro.6c00376 ↗
AbstractBibliografische Angaben

Abstract

Abstract Modeling neurodegenerative conditions in neural organoids presents a potential complement to existing preclinical translation pipelines. Prior neural organoid models have generally relied on human induced pluripotent stem cell (iPSC) lines containing disease-relevant alleles. However, this strategy limits temporal control over the initiation and progression of pathological events. In this study, we provide a proof-of-concept framework showing that neurodegenerative phenotypes can be triggered by inducible expression cassettes. We developed an iPSC line harboring doxycycline-inducible mutant MAPT, which encodes the microtubule-associated protein tau that is implicated in tauopathies. Induction of mutant MAPT via doxycycline treatment in differentiating neural organoids yielded accumulation of phosphorylated tau, which localized inside individual neuron somas within the cortical plate-like regions. Importantly, measured transcriptomic responses to tau overexpression bore key similarities to human clinical transcriptomic data. Taken together, we present an approach for controlling the initiation and progression of proteinopathy-like pathology in neural organoid systems.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →